EverSea Medicines to acquire Hasten Biopharmaceuticals
Everest Medicines will pay $250m in three instalments: $150m at closing, two $50m payments in 2028, 2029.
Drug Development
Jeito Capital secures over $1.2bn for new biopharma investments
RoosterBio and MineBio team up to expand MSC solutions access in China
Halozyme and Vertex sign deal for Hypercon technology
Apnimed obtains up to $150m in funds for commercial launch of AD109
Neurocrine to acquire Soleno in $2.9bn transaction
Aspect Biosystems receives funding for cellular medicine project
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer
